[Individualized infliximab therapy: pharmacokinetic monitoring]

Farm Hosp. 2015 Jan 1;39(1):59-60. doi: 10.7399/fh.2015.39.1.7791.

[Article in Spanish]

Authors

Eugènia Santacana-Juncosa¹, Ariadna Padullés-Zamora¹, Helena Colom Codina², Lorena Rodríguez-Alonso¹, Jordi Guardiola-Capon¹, Núria Padullés-Zamora¹

Affiliations

¹ Hospital Universitari de Bellvitge. IDIBELL. Hospitalet de LLobregat, Barcelona.. eugenia.santacana@bellvitgehospital.cat.
² Departamento de Farmacia y Tencología Farmacéutica. Facultad de Farmacia. Universidad de Barcelona. Barcelona.. eugenia.santacana@bellvitgehospital.cat.

PMID: 25680435
DOI: 10.7399/fh.2015.39.1.7791

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / pharmacokinetics
Antirheumatic Agents / therapeutic use*
Humans
Infliximab*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Infliximab